The Pandemic’s Impact on the Pediatric Cancer Research Landscape

• How is the pandemic changing current cancer care services?
• What is the current state of open clinical trials and how will new, near-term trials be affected?
• What is the impact on emerging new therapies and translational research?
• Are there any silver linings to all of this for childhood cancer research?

These answers and more are discussed in this special episode for cancer families where leaders from COG, the NCI and the pharmaceutical industry lead a community discussion about the pandemic's impact on all aspects of pediatric cancer research including clinical trials and standard cancer care services, followed by Q&A with questions from families and attendees.

 

We are joined by:
- Peter Adamson, MD – former Chair, Children's Oncology Group (COG) and current Global Head, Oncology Development & Pediatric Innovation, Sanofi

- Mark Kieran, MD, PhD – Pediatric Clinical Trial Lead, Bristol Myers Squibb

- Jeffery J. Auletta, MD - Director of the Blood and Marrow Transplant (BMT) Program and the Host Defense and Immunocompromised Infectious Diseases Program at Nationwide Children's Hospital.

- Carol Thiele, Ph.D, Deputy Chief, National Cancer Institute (NCI) Pediatric Oncology Branch

- Prof. Pamela Kearns President, European Society of Pediatric Oncology (SIOPE), Director of Cancer Research UK Clinical Trials Unit

Moderated by: Timothy P. Cripe, MD, PhD – Chief of Hematology and Oncology at Nationwide Children’s Hospital

Hosted by: Solving Kids' Cancer US & UK, and Max Cure Foundation